» Articles » PMID: 31739430

Interaction of the P.Q141K Variant of the Gene with Clinical Data and Cytokine Levels in Primary Hyperuricemia and Gout

Overview
Journal J Clin Med
Specialty General Medicine
Date 2019 Nov 20
PMID 31739430
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Gout is an inflammatory arthritis influenced by environmental risk factors and genetic variants. The common dysfunctional p.Q141K allele of the gene affects gout development. We sought after the possible association between the p.Q141K variant and gout risk factors, biochemical, and clinical determinants in hyperuricemic, gouty, and acute gouty arthritis cohorts. Further, we studied the correlation of p.Q141K allele and levels of pro-/anti-inflammatory cytokines. Coding regions of the gene were analyzed in 70 primary hyperuricemic, 182 gout patients, and 132 normouricemic individuals. Their genotypes were compared with demographic and clinical parameters. Plasma levels of 27 cytokines were determined using a human multiplex cytokine assay. The p.Q141K variant was observed in younger hyperuricemic/gout individuals ( = 0.0003), which was associated with earlier disease onset ( = 0.004), trend toward lower BMI ( = 0.056), and C-reactive protein (CRP, = 0.007) but a higher glomerular filtration rate (GFR, = 0.035). Levels of 19 cytokines were higher, mainly in patients with acute gouty arthritis ( < 0.001), irrespective of the presence of the p.Q141K variant. The p.Q141K variant influences the age of onset of primary hyperuricemia or gout and other disease-linked risk factors and symptoms. There was no association with cytokine levels in the circulation.

Citing Articles

Potential association between magnesium depletion score and hyperuricemia in American adults, a cross-sectional study based on NHANES 2003-2018.

Li Z, Wu M, Kong S, Xiao B Prev Med Rep. 2025; 51:103000.

PMID: 40034986 PMC: 11875140. DOI: 10.1016/j.pmedr.2025.103000.


Hyperuricemia and its related diseases: mechanisms and advances in therapy.

Du L, Zong Y, Li H, Wang Q, Xie L, Yang B Signal Transduct Target Ther. 2024; 9(1):212.

PMID: 39191722 PMC: 11350024. DOI: 10.1038/s41392-024-01916-y.


Anti-inflammatory Properties of Tongfeng Li'an Granules in an Acute Gouty Arthritis Rat Model.

Zhao X, Long Z, Zhong H, Lu R, Wei J, Li F ACS Omega. 2024; 9(32):34303-34313.

PMID: 39157086 PMC: 11325525. DOI: 10.1021/acsomega.4c00056.


Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment.

Kvasnicka A, Friedecky D, Brumarova R, Pavlikova M, Pavelcova K, Masinova J Arthritis Res Ther. 2023; 25(1):234.

PMID: 38042879 PMC: 10693150. DOI: 10.1186/s13075-023-03204-6.


Joint Application of Multiple Inflammatory Cytokines in Diagnosis of Gout Flare.

Yu H, Xue W, Yu H, Gu H, Qin L, Peng A J Inflamm Res. 2023; 16:1771-1782.

PMID: 37113627 PMC: 10128086. DOI: 10.2147/JIR.S408929.


References
1.
Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Garcia Rodriguez L . Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford). 2011; 50(5):973-81. DOI: 10.1093/rheumatology/keq363. View

2.
Zhou Y, Fang L, Jiang L, Wen P, Cao H, He W . Uric acid induces renal inflammation via activating tubular NF-κB signaling pathway. PLoS One. 2012; 7(6):e39738. PMC: 3382585. DOI: 10.1371/journal.pone.0039738. View

3.
Schlesinger N, Thiele R . The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis. 2010; 69(11):1907-12. DOI: 10.1136/ard.2010.128454. View

4.
Shen S, Callaghan D, Juzwik C, Xiong H, Huang P, Zhang W . ABCG2 reduces ROS-mediated toxicity and inflammation: a potential role in Alzheimer's disease. J Neurochem. 2010; 114(6):1590-604. DOI: 10.1111/j.1471-4159.2010.06887.x. View

5.
Vasudevan A, Wu H, Xydakis A, Jones P, OBrian Smith E, Sweeney J . Eotaxin and obesity. J Clin Endocrinol Metab. 2005; 91(1):256-61. DOI: 10.1210/jc.2005-1280. View